

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



30th July, 2021

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

Sub: Submission of Quick Result.

We refer to the above mentioned subject, we herewith submit to the Exchange the quick results for the quarter ended 30th June, 2021 as approved by the Board of Directors at their meeting held on 30th July, 2021.

This is for the information and records of the Exchange, Please.

Thanking You,

Yours Faithfully,
For **Krebs Biochemicals & Industries Limited**



Taruni Banda

Company Secretary

Encl as above

KREBS BIOCHEMICALS & INDUSTRIES LIMITED
CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031
Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021


(Rs. In Lacs)

Sl.No	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
	PART - 1				
1	Revenue from Operations				
	a) Net Sales / Income from Operations	539.50	1,307.42	768.00	3,860.64
	b) Other Operating Income	136.04	278.51	388.90	1,509.40
2	Other Income	2.98	44.41	5.02	62.13
3	Total Income from operations (1+2)	678.52	1,630.34	1,161.92	5,432.17
4	Expenses				
	a) Cost of Material Consumed	442.08	603.67	743.82	2,562.26
	b) Changes in Inventories of Finished goods, Work-In-Progress	(68.45)	290.50	(362.76)	32.49
	c) Employee Benefits Expenses	330.75	402.30	428.41	1,582.78
	d) Finance Costs	151.16	149.32	123.22	627.90
	e) Depreciation and Amortisation Expense	141.60	141.34	123.69	512.40
	f) Other Manufacturing Expenses	543.43	646.12	703.53	2,628.48
	g) Other Expenses	80.30	95.75	74.16	321.72
	Total Expenses (4)	1,620.87	2,329.00	1,834.07	8,268.03
5	Profit / (Loss) before exceptional items and tax (3±4)	(942.35)	(698.66)	(672.15)	(2,835.86)
6	Exceptional Items:				
	a) Depletion in Value of Inventory	-	-	-	-
	b) Amounts Written back / (written off)	-	-	-	-
	c) Prior Period Income/(Expenditure)	-	-	-	-
	d) Profit on sale of Fixed Assets	-	-	-	-
7	Profit / (Loss) before Tax (5 ± 6)	(942.35)	(698.66)	(672.15)	(2,835.86)
8	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-	-	-	-
9	Profit / (Loss) for the period (7 ± 8)	(942.35)	(698.66)	(672.15)	(2,835.86)
10	Other Comprehensive Income (OCI)				
	i) Items that will not be reclassified to profit or Loss		25.51	-	25.51
	ii) Income tax relating to items that will not be reclassified to profit or Loss	-	(8.25)	-	-
	iii) Items that will be reclassified to profit or Loss	-	(8.25)	-	(8.25)
	iv) Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)		17.26	-	17.26
11	Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(942.35)	(681.40)	(672.15)	(2,818.60)
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	1962.06	1962.06	1962.06
13	Other Equity excluding revaluation reserve				(7,340.43)
14	Earning Per Share (of Rs.10/- each) (not Annualised)				
	a) Basic	(4.37)	(3.47)	(3.43)	(14.53)
	b) Diluted	(4.37)	(3.47)	(3.43)	(14.53)
15	Net Worth (including Retained Earnings)				(4,273.29)

See accompanying notes to the Financial results

- The above results have been reviewed by the Audit Committee at its meeting held on 30th July 2021 and approved by the Board of Directors of the Company at its meeting held on 30th July 2021. The results are subjected to limited review by statutory auditors.
- The Company is operating in one segment only hence no segment results have been disclosed.
- The figures for the preceding quarter ended 31.03.2021 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to third quarter of the relevant financial year
- The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes to future economic conditions.
- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.

Place: Hyderabad
Date: 30.07.2021



Avinash Ravi
Managing Director
DIN: 01616152

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031
Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

Additional disclosures as per Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sl No	Particulars	As at 30-06-2021		As at 31-03-2021	
1	Debt-equity ratio [no.of times]*	(2.64)		(2.37)	
2	i) Last due date for the payment of dividend of Non-convertible Redeemable preference shares (NCRPS)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA		NA	
	ii) Whether Dividend has been paid on due dates	NA		NA	
3	i) Last due date for the repayment of principal of NCRPS	NA		NA	
	ii) Whether principal has been repaid on due dates	NA		NA	
4	Next due date and amount for payment of dividend of NCRPS	(Rs.Lacs)	Date	(Rs.Lacs)	Date
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
5	Next due date and amount for the repayment of principal of NCRPS (falling due within next one year period)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
6	Next due date and amount for the repayment of principal of CPs (falling due within next one year period)	NA	NA	NA	NA
		As at 30-06-2021		As at 31-03-2021	
	Particulars	(Rs.Lacs)		(Rs.Lacs)	
7	Debt Service Coverage ratio **	(0.06)		(0.16)	
8	Interest Service coverage ratio ***	(5.23)		(3.52)	
9	Outstanding redeemable preference shares (quantity and value)				
	Quantity	30.00		30.00	
	Value	3,000.00		3,000.00	
10	Capital redemption reserve/debenture redemption reserve	-		-	
11	Net Worth****	(5,108.80)		(5,417.76)	
12	Net Profit/(Loss) after tax (Including Other comprehensive Income)	(942.35)		(2,818.60)	
13	Earning per share	(3.43)		(14.53)	

Note:

- * Debt-Equity Ratio = Total Borrowings divided by Equity
- ** DSCR = EBITDA (Earnings before interest, Tax, depreciation and Amortization) divided by (Interest expenses & principal amount on Short & Long Tem borrowings)
- *** ISCR = Profit before interest and exceptional items divided by interest expense
- **** Net worth as per section 2(57) of Companies Act, 2013 (aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation).
- The above results have been reviewed by the Audit Committee at its meeting held on 30th July 2021 and approved by the Board of Directors of the Company at its meeting held on 30th July 2021. The results are subjected to limited review by statutory auditors.

Place: Hyderabad
Date:30.07.2021



Avinash Ravi

Avinash Ravi
Managing Director
DIN : 01616152



Limited Review Report

**Review Report to
The Board of Directors,
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30th June, 2021** and the year to date from 1st April 2021 to 30th June 2021 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani &Co.
Chartered Accountants
Firm Registration No: 012139S

Place : Hyderabad
Date : 30/07/2021

CA S Kavitha Padmini
Partner
Membership no: 229966
UDIN # 21229966AAAADM5838